Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry

Circulation

Volumn 113, Issue 11, 2006, Pages 1434-1441

  Urban, Philip ^a   Gershlick, Anthony H ^b   Guagliumi, Giulio ^c   Guyon, Philippe ^d   Lotan, Chaim ^e   Schofer, Joachim ^f   Seth, Ashok ^g   Sousa, J Eduardo ^h   Wijns, William ⁱ   Berge, Claude ^j   Deme, Monika ^k   Stoll, Hans Peter ^k  

^a LA TOUR HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c OSPEDALI RIUNITI   (Italy)

^d Centre Cardiologique du Nord   (France)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^f UNIVERSITY HEART CENTER HAMBURG   (Germany)

^g Max Heart and Vascular Institute   (India)

^h INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

ⁱ OLV HOSPITAL   (Belgium)

^j Hesperion Ltd   (Switzerland)

^k Cordis Clinical Research Europe ^*  (Belgium)

more..

Author keywords

Coronary disease; Registries; Revascularization; Stents; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; INSULIN; RAPAMYCIN; THIENO[2,3 B]PYRIDINE DERIVATIVE; TICLOPIDINE; DRUG DERIVATIVE; FIBRINOLYTIC AGENT;

ADULT; AGED; ANGIOGRAPHY; ARTERY CALCIFICATION; ARTICLE; CORONARY ARTERY DISEASE; DEMOGRAPHY; DRUG ELUTING STENT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERNET; MAJOR CLINICAL STUDY; MALE; POSTMARKETING SURVEILLANCE; PREDICTION; PRIORITY JOURNAL; REGISTER; REGRESSION ANALYSIS; SAFETY; THROMBOSIS; TREATMENT INDICATION; CAUSE OF DEATH; COMORBIDITY; CORONARY ARTERY OBSTRUCTION; DRUG IMPLANT; EVALUATION; FOLLOW UP; HEART INFARCTION; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RESTENOSIS; RISK FACTOR; STATISTICS; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED STATES;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CAUSE OF DEATH; COMORBIDITY; CORONARY DISEASE; CORONARY RESTENOSIS; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG IMPLANTS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INTERNET; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; RISK FACTORS; SIROLIMUS; STENTS; THROMBOSIS; TICLOPIDINE; UNITED STATES;

EID: 33645835356     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.532242     Document Type: Article

References (34)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R, RAVEL Study Group. Randomized study with the sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions: a randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
3. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G; E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093-1099.
4. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ; C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110-1115.
5. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR, Guermonprez J-L, Eltchaninoff H, Blanchard D, Bartorelli A, Laarman G-J, Perin MA, Sousa JE, Schuler G, Molnar F, Guagliumi G, Colombo A, Ban Hayashi E, Wülfert E. Long-term suppression of restenosis by sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005;111:1040-1044.
6. Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, Centemero M, Maldonado G, Abizaid AS, Pinto I, Falotico R, Jaeger J, Popma JJ, Serruys PW. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2003;107:24-27.
7. Degertekin M, Arampatzis CA, Lemos PA, Saia F, Hoye A, Daemen J, Tanabe K, Lee CH, Hofma SJ, Sianos G, McFadden E, van der Giessen W, Smits PC, de Feyter PJ, van Domburg RT, Serruys PW. Very long sirolimus-eluting stent implantation for de novo coronary lesions. Am J Cardiol. 2004;93:826-829.
8. Arampatzis CA, Hoye A, Lemos PA, Saia F, Tanabe K, Degertekin M, Sianos G, Smits PC, van der Giessen WJ, McFadden E, van Domburg R, de Feyter P, Serruys PW. Elective sirolimus-eluting stent implantation for multivessel disease involving significant LAD stenosis: one-year clinical outcomes of 99 consecutive patients: the Rotterdam experience. Cathet Cardiovasc Interv. 2004;63:57-60.
9. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109:190-195.
10. Zahn R, Hamm CW, Zeymer U, Schneider S, Nienaber CA, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Schobel WA, Sabin G, Senges J; Deutsche Cypher-Register. Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany: results from the prospective multicenter German Cypher Registry [in German]. Herz. 2004;29:181-186.
11. Mikhail GW, Airoldi F, Tavano D, Chieffo A, Rogacka R, Carlino M, Montorfano M, Sangiorgi G, Corvaja N, Michev I, Orlic D, Di Mario C, Colombo A. The use of drug eluting stents in single and multivessel disease: results from a single centre experience. Heart. 2004;90:990-994.
12. Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA, Hoye A, McFadden E, Sianos G, Smits PC, van der Giessen WJ, de Feyter P, van Domburg RT, Serruys PW. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43:704-708.
13. Ong ATL, Hoye A, Aokid J, van Mieghem CAG, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PPT, de Feyter P, van Domburg RT, Serruys PW. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005;45:947-953.
14. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP Jr, Chauhan MS, Rodriguez O, Kuntz RE. Thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-1971.
15. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, Ho KK, Cohen DJ, Garcia LA, Cutlip DE, Carrozza JP Jr. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation. 2004;109:1930-1932.
16. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665-1671.
17. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942-1947.
18. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188-1193.
19. Guagliumi G, Farb A, Musumeci G, Valsecchi O, Tespili M, Motta T, Virmani R. Images in cardiovascular medicine: sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation. 2003;107:1340-1341.
20. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-1521.
21. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705.
22. Waksman R, Ajani AE, Pinnow E, Cheneau E, Leborgne L, Dieble R, Bui AB, Satler LF, Pichard AD, Kent KK, Lindsay J. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing γ-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation. 2002;106:776-778.
23. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation. 1998;98:1597-1603.
24. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, van Hout BA; Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117-1124.
25. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, Louvard Y, Desmedt B, Di Mario C, Leon MB. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004;109:1244-1249.
26. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabaté M, Escaned J, Bañuelos C, Fernández-Ortiz A, Macaya C. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-959.
27. Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364:583-591.
28. Chieffo A, Bonizzoni E, Orlic D, Stankovic G, Rogacka R, Airoldi F, Mikhail GW, Montorfano M, Michev I, Carlino M, Colombo A. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation. 2004;109:2732-2736.
29. Goy JJ, Urban P, Seydoux C, De Benedetti E, Stauffer JC. Use of sirolimus-eluting coronary stents in routine clinical practice. Cathet Cardiovasc Interv. 2004;62:26-29.
30. Gupta V, Aravamuthan BR, Baskerville S, Smith SK, Gupta V, Lauer MA, Fischell TA. Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a large-scale, "real world" registry. J Invas Cardiol 2004;16:304-310.
31. Carter AJ, Bailey L, Devries J, Hubbard B. The effects of uncontrolled hyperglycemia on thrombosis and formation of neointima after coronary stent placement in a novel diabetic porcine model of restenosis. Coron Artery Dis. 2000;11:473-479.
32. Katz S, Costa MA, Berger PB, Reynolds L, Keim E, Cohen S. The CYPHER U.S. Post Market Surveillance Registry (e-Cypher): six month results in acute myocardial infarction patients. J Am Coll Cardiol. 2005;45(suppl A):84A. Abstract.
33. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
34. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation: early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.